Phio Pharmaceuticals Corp. financial data

Symbol
PHIO on Nasdaq
Industry
Pharmaceutical Preparations
Location
11 Apex Drive, Suite 300 A, Pmb 2006, Marlborough, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
RXi Pharmaceuticals Corp (to 11/14/2018)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 457 % -17.2%
Debt-to-equity 27.2 % +64%
Return On Equity -143 % -19%
Return On Assets -112 % -13.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 861K shares -61.3%
Common Stock, Shares, Outstanding 510K shares -74.3%
Entity Public Float 5.7M USD -40%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 510K shares +166%
Weighted Average Number of Shares Outstanding, Diluted 510K shares +166%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.83M USD -36.8%
General and Administrative Expense 3.84M USD -20.1%
Operating Income (Loss) -8.8M USD +29.3%
Nonoperating Income (Expense) 123K USD
Net Income (Loss) Attributable to Parent -8.68M USD +30.4%
Earnings Per Share, Basic 7.13 USD/shares +72.7%
Earnings Per Share, Diluted 7.13 USD/shares +72.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.7M USD -58.5%
Assets, Current 5.29M USD -56%
Property, Plant and Equipment, Net 1K USD -99.4%
Operating Lease, Right-of-Use Asset 0 USD -100%
Other Assets, Noncurrent 3K USD -50%
Assets 5.3M USD -56.9%
Accounts Payable, Current 335K USD -47.7%
Employee-related Liabilities, Current 222K USD -45.6%
Accrued Liabilities, Current 1.19M USD -27.9%
Liabilities, Current 1.52M USD -36.3%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 1.63M USD -17.2%
Retained Earnings (Accumulated Deficit) -143M USD -6.45%
Stockholders' Equity Attributable to Parent 3.77M USD -61.9%
Liabilities and Equity 5.3M USD -56.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.01M USD +25.7%
Net Cash Provided by (Used in) Financing Activities -4M USD -10426%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 510K shares -74.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.7M USD -58.6%
Deferred Tax Assets, Valuation Allowance 2.55M USD -84.9%
Deferred Tax Assets, Gross 2.56M USD -84.9%
Operating Lease, Liability 0 USD -100%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 35K USD -80%
Property, Plant and Equipment, Gross 1.14M USD -15.9%
Operating Lease, Liability, Current 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Two 35K USD -75%
Lessee, Operating Lease, Liability, to be Paid, Year One 35K USD -75%
Operating Lease, Weighted Average Discount Rate, Percent 0 pure -106%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid, Year Three 35K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 774K USD -93.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 100M shares +900%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 105K USD -23.4%
Additional Paid in Capital 147M USD +1.76%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1K USD -93.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%